Search Result

Results for "

protein kinase A (PKA)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PKA (67) 5-HT Receptor (1) Akt (3) AMPK (2) Antibiotic (3) Apoptosis (15) Autophagy (10) Bacterial (3) Bcl-2 Family (2) c-Kit (4) Calcium Channel (10) CaMK (2) Caspase (2) CMV (2) COX (1) Cyclic GMP-AMP Synthase (3) EGFR (4) ERK (3) Fungal (2) G Protein-coupled Receptor Kinase (GRK) (3) HIV (4) Isotope-Labeled Compounds (2) MARCKS (1) mTOR (2) Myosin (4) NO Synthase (3) PAK (2) Parasite (2) PARP (2) Phosphodiesterase (PDE) (3) PKC (30) Ras (1) Reactive Oxygen Species (ROS) (8) Reference Standards (8) ROCK (10) Src (1) Syk (1) Trk Receptor (1) TRP Channel (1) Tyrosine Hydroxylase (1) VEGFR (3)
By Research Areas:	Cancer (39) Cardiovascular Disease (10) Endocrinology (1) Infection (6) Inflammation/Immunology (13) Metabolic Disease (12) Neurological Disease (12)
Oligonucleotides:	Antisense Oligonucleotides (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

GMP Molecules

Targets Recommended: PKA

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15141

Staurosporine Maximum Cited Publications 207 Publications Verification Antibiotic AM-2282; STS; AM-2282	PKC PKA Apoptosis Bacterial Fungal Antibiotic	Infection Cancer
Staurosporine is a potent, ATP-competitive and non-selective inhibitor of protein kinases with IC₅₀s of 6 nM, 15 nM, 2 nM, and 3 nM for PKC, *PKA, c-Fgr, and Phosphorylase kinase* respectively. Staurosporine also inhibits TAOK2 with an IC₅₀ of 3 μM. Staurosporine is an apoptosis inducer .

HY-B0764

Bucladesine sodium 40+ Cited Publications Dibutyryl cAMP sodium; DBcAMP sodium	PKA Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-15979A

H-89 dihydrochloride 175+ Cited Publications	PKA Autophagy	Others
H-89 dihydrochloride is a potent and selective inhibitor of protein kinase A (PKA) with an IC₅₀ of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase.

HY-12306

8-Bromo-cAMP sodium salt 35+ Cited Publications 8-Br-Camp sodium salt	PKA Apoptosis	Cancer
8-Bromo-cAMP sodium (8-Br-Camp) sodium salt, a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (PKA). 8-Bromo-cAMP sodium salt has anti-proliferative and apoptotic effects against cancer cells .

HY-12306A

8-Bromo-cAMP 35+ Cited Publications 8-Br-Camp	PKA Apoptosis	Cancer
8-Bromo-cAMP (8-Br-Camp), a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (PKA). 8-Bromo-cAMP has anti-proliferative and apoptotic effects against cancer cells .

HY-10341

Fasudil Hydrochloride 25+ Cited Publications HA-1077 Hydrochloride; AT-877 Hydrochloride	ROCK Calcium Channel Autophagy PKA PKC HIV	Cancer
Fasudil (HA-1077; AT877) Hydrochloride is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and *PKA, PKC, PKG*, respectively. Fasudil Hydrochloride is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-10230

Midostaurin 35+ Cited Publications PKC412; CGP 41251	PKC VEGFR c-Kit NO Synthase Apoptosis	Cancer
Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, *PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ* and VEGFR1/2 with IC₅₀s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .

HY-N6732

K-252a 25+ Cited Publications SF2370; Antibiotic K 252a; Antibiotic SF 2370	Autophagy PKA PKC Trk Receptor CaMK	Infection Inflammation/Immunology
K-252a, a staurosporine analog, inhibits **protein kinase, with IC₅₀** values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca ²⁺/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively . K-252a is a potent inhibitor (IC₅₀ of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene .

HY-N6791

KT5823 10+ Cited Publications	PKA PKC Bacterial Apoptosis Antibiotic	Infection Inflammation/Immunology
KT5823, a selective the cGMP-dependent protein kinase (PKG) inhibitor with an K_i value of 0.23 μM, it also inhibits *PKA* and PKC with K_i values of 10 μM and 4 μM, respectively. KT5823 is a Staurosporine-related protein kinase inhibitor, increases thyroid-stimulating hormone-induced (Na ⁺/I ^- symporter) NIS expression, and iodide uptake in thyroid cells. KT5823 arrests cells after the G0/G1 boundary and causes increases in the levels of apoptotic DNA fragmentation .

HY-10341A

Fasudil 25+ Cited Publications HA-1077; AT877	ROCK Calcium Channel Autophagy PKA PKC	Cancer
Fasudil (HA-1077; AT877) is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and *PKA, PKC, PKG*, respectively. Fasudil is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-B0764A

Bucladesine hemicalcium 40+ Cited Publications Dibutyryl cAMP hemicalcium; DBcAMP hemicalcium	PKA Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) hemicalcium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-N0281

Daphnetin 5+ Cited Publications 7,8-Dihydroxycoumarin	EGFR PKA PKC Autophagy Apoptosis AMPK Akt mTOR Reactive Oxygen Species (ROS) Caspase Bcl-2 Family PARP Parasite	Cardiovascular Disease Inflammation/Immunology Cancer
Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative can be found in plants of the Genus Daphne, is a potent, oral active **protein kinase inhibitor, with IC₅₀s** of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively. Daphnetin triggers ROS-induced cell apoptosis and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway. Daphnetin has anti-inflammation activitity and inhibits TNF-α, IL-1β, ROS, and MDA production. Daphnetin has schizontocidal activity against malaria parasites. Daphnetin can be used for rheumatoid arthritis , cancer and anti-malarian research .

HY-P0248

Kemptide 1 Publications Verification	PKA	Metabolic Disease
Kemptide is a synthetic heptapeptide that acts as a specific substrate for cAMP-dependent protein kinase (PKA).

HY-108254

Bisindolylmaleimide IV Arcyriarubin A	PKC CMV	Infection
Bisindolylmaleimide IV (Arcyriarubin A) is a potent protein kinase C (PKC) inhibitor, with IC₅₀s ranging from 0.1 to 0.55 μM. Bisindolylmaleimide IV also inhibits PKA (IC₅₀=3.1-11.8μM) . Bisindolylmaleimide IV is a potent, selective inhibitor of human cytomegalovirus (HCMV) replication in cell culture with an IC₅₀ of 0.2 μM .

HY-111673

8-CPT-Cyclic AMP sodium 8-CPT-cAMP sodium; 8-(p-Chlorophenylthio)-cAMP sodium	PKA Phosphodiesterase (PDE)	Inflammation/Immunology
8-CPT-Cyclic AMP (8-CPT-cAMP) sodium is a selective activator of cyclic AMP-dependent protein kinase (PKA). 8-CPT-Cyclic AMP sodium is also a potent inhibitor of the cyclic GMP-specific phosphodiesterase (PDE VA) with an IC₅₀ of 0.9 μM. 8-CPT-Cyclic AMP sodium also inhibits PDE III and PDE IV with IC₅₀Epac and is a potent Epac activator .

HY-115732

PKA-IN-1 1 Publications Verification	PKA	Inflammation/Immunology
PKA-IN-1 is a potent and selective cyclic AMP-dependent protein kinase (PKA) catalytic subunit (cAK) inhibitor with an IC₅₀ of 0.03 μM. PKA-IN-1 inhibits cAK in a fashion that is competitive with respect to ATP as substrate .

HY-B1898

Metadoxine	PKA	Metabolic Disease
Metadoxine blocks adipocyte differentiation in association with inhibition of the protein kinase A-cAMP response element binding protein *(PKA-CREB)* pathway.

HY-100984

HA-100 1 Publications Verification	PKA PKC Myosin ROCK	Cancer
HA-100 is a potent **protein kinase inhibitor, with IC₅₀s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG)*, cAMP-dependent protein* kinase (PKA), protein kinase C (PKC) and *MLC-kinase, respectively. HA-100 also used as a ROCK* inhibitor .

HY-P0222

PKI(5-24) 3 Publications Verification	PKA	Others
PKI(5-24) is a potent, competitive, and synthetic peptide inhibitor of *PKA* (cAMP-dependent protein kinase), with a K_i of 2.3 nM. PKI(5-24) corresponds to residues 5-24 in the naturally occurring heat-stable protein kinase inhibitor .

HY-P1290

PKA Inhibitor Fragment (6-22) amide 5 Publications Verification PKI-(6-22)-amide	PKA	Neurological Disease
PKA Inhibitor Fragment (6-22) amide is a highly potent and specific competitive inhibitor of *PKA, with K_i* values of 1.7 nM and 1.6 nM against human and bovine *PKA* catalytic subunits, respectively. The IC₅₀ of PKA Inhibitor Fragment (6-22) amide targeting bovine PKA is 8.6 nM. PKA Inhibitor Fragment (6-22) amide effectively abolishes PKA activity in mouse brain and spinal cord, and exerts in vivo efficacy via intracerebroventricular administration. PKA Inhibitor Fragment (6-22) amide significantly reverses low-dose morphine analgesic tolerance in mice and blocks photoaffinity labeling of cAMP-dependent protein kinase. PKA Inhibitor Fragment (6-22) amide can be applied to research in fields related to the mechanism of morphine analgesic tolerance and skin wound healing .

HY-P1290A

PKA Inhibitor Fragment (6-22) amide TFA 5 Publications Verification PKI-(6-22)-amide TFA	PKA	Neurological Disease
PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependent **protein kinase A (PKA), with a K_i** of 2.8 nM. PKA Inhibitor Fragment (6-22) amide TFA can significantly reverse antinociceptive tolerance in mice .

HY-10341C

Fasudil dihydrochloride 25+ Cited Publications HA-1077 dihydrochloride; AT-877 dihydrochloride	Calcium Channel ROCK PKA PKC Autophagy HIV	Cancer
Fasudil (HA-1077; AT877) dihydrochloride is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and *PKA, PKC, PKG*, respectively. Fasudil dihydrochloride is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-P10602

PKA Regulatory Subunit II Substrate RII phosphopeptide	PKA	Others
PKA Regulatory Subunit II Substrate (RII phosphopeptide) is a tool peptide derived from the regulatory subunit Type II (RII) of cyclic AMP-dependent protein kinase (PKA). PKA Regulatory Subunit II Substrate is commonly used to mimic the phosphorylation of protein kinases and as a specific substrate for protein phosphatases to assess the activities of these enzymes .

HY-108262

UCN-02 7-epi-Hydroxystaurosporine	PKC PKA	Cancer
UCN-02 (7-epi-Hydroxystaurosporine) is a selective protein kinase C (PKC) inhibitor with a PKC IC₅₀ value of 62 nM and a *PKA* IC₅₀ value of 0.25 μM. UCN-02 can be produced by Streptomyces strain N-126. UCN-02 can be used for the research of breast carcinoma .

HY-109562A

CCG258208 hydrochloride 1 Publications Verification GRK2-IN-1 hydrochloride	G Protein-coupled Receptor Kinase (GRK)	Cardiovascular Disease
CCG258208 (GRK2-IN-1) hydrochloride is a potent and selective GRK2 (*G protein-coupled receptor kinase* 2) inhibitor (IC₅₀=30 nM) while maintaining 230-fold selectivity over GRK5 (IC₅₀=7.09 μM) and more than 2500-fold selectivity over GRK1 (IC₅₀*=87.3 μM), PKA*, and ROCK1. CCG258208 hydrochloride can be used in heart failure research .

HY-B0764B

Bucladesine Dibutyryl cAMP; DBcAMP	PKA Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-P1597

Malantide 1 Publications Verification	PKA PKC	Cancer
Malantide is a synthetic dodecapeptide derived from the site phosphorylated by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide is a highly specific substrate for *PKA* with a K_m of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts . Malantide is also an efficient substrate for PKC with a K_m of 16 μM .

HY-108047

MK-0873	Phosphodiesterase (PDE)	Metabolic Disease Inflammation/Immunology
MK-0873 is a selective phosphodiesterase-4 (PDE4) inhibitor. MK-0873 increases intracellular levels of cyclic adenosine phosphate (cAMP) by inhibiting the activity of the PDE4 enzyme and subsequently activates protein kinase A (PKA). Activated PKA inhibits the activity of inflammatory cells and leads to direct relaxation of airway smooth muscle. MK-0873 can be used in studies of chronic obstructive pulmonary disease (COPD) .

HY-137640A

Sp-8-Br-cAMPS sodium	PKA	Inflammation/Immunology
Sp-8-Br-cAMPS sodium is a cAMP analog, which performs a protein kinase A (PKA) activating activity with EC₅₀ of 360 nM. Sp-8-Br-cAMPS sodium inhibits proliferation of T cells and the haemocyte non-self response in Lepidoptera larve .

HY-15141R

Staurosporine (Standard) Antibiotic AM-2282 (Standard); STS (Standard); AM-2282 (Standard)	Reference Standards PKC PKA Apoptosis Bacterial Fungal Antibiotic	Infection Cancer
Staurosporine (Standard) is the analytical standard of Staurosporine. This product is intended for research and analytical applications. Staurosporine is a potent, ATP-competitive and non-selective inhibitor of protein kinases with IC50s of 6 nM, 15 nM, 2 nM, and 3 nM for PKC, PKA, c-Fgr, and Phosphorylase kinase respectively. Staurosporine also inhibits TAOK2 with an IC50 of 3 μM. Staurosporine is an apoptosis inducer[1][2][3][4][5].

HY-137325A

2-Chloro-ATP sodium	Calcium Channel	Metabolic Disease
2-Chloro-ATP sodium (2-Chloro ATP) is an adenine nucleotide and an analog of ATP. It is an antagonist of the purinergic P2Y1 receptor and inhibits intracellular calcium mobilization induced by ADP (HY-W010918) in Jurkat cells expressing the human receptor (Ki=2.3 μM). 2-Chloro-ATP sodium is an agonist of the purinergic P2X receptor and induces inward currents in HEK293 cells expressing human bladder smooth muscle or rat PC12 forms of the receptor (EC50=0.5 and 2.5 μM). 2-Chloro-ATP sodium induces relaxation of precontracted guinea pig cecal strips in a concentration-dependent manner. 2-Chloro-ATP sodium has been used to study the substrate specificity of cyclic nucleotide-dependent protein kinases such as protein kinase A (PKA) and PKG.

HY-B0764G

Bucladesine sodium Dibutyryl cAMP sodium; DBcAMP sodium	PKA Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium (GMP) is a Bucladesine sodium (HY-B0764) produced by using GMP guidelines. Bucladesine (Dibutyryl cAMP; DBcAMP) is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-123520

GSK299115A	G Protein-coupled Receptor Kinase (GRK) PKA	Cancer
GSK299115A is a *G Protein-coupled Receptor Kinase* (GRK) and PKA** inhibitor .

HY-P2624A

st-Ht31 ammonium	PAK	Metabolic Disease
st-Ht31 ammonium is a membrane-permeable peptide inhibitor of?protein kinase A (PKA) anchoring. st-Ht31 ammonium induces robust cholesterol/phospholipid efflux. st-Ht31 ammonium completely reverses foam cell formation and restores the metabolic health of macrophage .

HY-100923

H-9 Dihydrochloride	PKA 5-HT Receptor EGFR	Neurological Disease
H-9 Dihydrochloride is a *PKA* (protein kinase) inhibitor. H-9 Dihydrochloride (10 μM) significantly reduces the excitatory response to 5-HT. H-9 Dihydrochloride also has a direct effect on pharyngeal activity. H-9 Dihydrochloride inhibits signal-transduction and cell growth in EGF (epidermal growth factor)-dependent epithelial cell lines .

HY-N0521R

(-)-Gallocatechin (Standard)	Reference Standards Reactive Oxygen Species (ROS)	Metabolic Disease Cancer
(-)-Gallocatechin (Standard) is the analytical standard of (-)-Gallocatechin. This product is intended for research and analytical applications. (-)-Gallocatechin, an epimer of (-)-Epigallocatechin (EGC), is contained in various tea products. (-)-Gallocatechin has antioxidant activities. (-)-Gallocatechin is the main active component in green tea extract (HTP-GTE) responsible for its effect of improving age-related cognitive impairments involving protein kinase A (PKA) pathway .

HY-123468

HA-1004	Cyclic GMP-AMP Synthase PKA ERK Tyrosine Hydroxylase Calcium Channel	Cardiovascular Disease Metabolic Disease
HA-1004 is a selective inhibitor of PKA, which can inhibit lipolysis and induce vascular relaxation. HA-1004 is also a dual inhibitor of cyclic GMP-dependent protein kinase and cyclic AMP-dependent protein, and is involved in smooth muscle, second messenger, cyclic AMP and cyclic GMP regulation mechanisms. HA-1004 is an antagonist for calcium, that can be used as a vasodilator to inhibit the contraction of rabbit aortic strips, or to antagonize ERK and tyrosine hydroxylase (TH) phosphorylation in morphine abstinence rat models .

HY-109562

CCG258208 GRKs-IN-1	G Protein-coupled Receptor Kinase (GRK)	Cardiovascular Disease
CCG258208 (GRK2-IN-1) is a potent and selective GRK2 (*G protein-coupled receptor kinase* 2) inhibitor (IC₅₀=30 nM) while maintaining 230-fold selectivity over GRK5 (IC₅₀=7.09 μM) and more than 2500-fold selectivity over GRK1 (IC₅₀*=87.3 μM), PKA*, and ROCK1. CCG258208 can be used in heart failure research .

HY-121197

Balanol Ophiocordin; Azepinostatin	MARCKS PKA PKC	Others
Balanol (Ophiocordin; Azepinostatin) is a potent and ATP competitive *PKC/PKA* inhibitor against human PKC isozymes α, β-I, β-II, γ, δ, ε, η (IC₅₀s=4-9 nM) and ζ (IC₅₀=150 nM). Balanol also blocks the phosphorylation of *cyclic AMP response element-binding protein* (CREB) and myristoylated alanine-rich C kinase substrate (MARCKS)*. Balanol can be isolated from the fungus Verticillium balanoides* .

HY-B0764R

Bucladesine sodium (Standard) Dibutyryl cAMP sodium (Standard); DBcAMP sodium (Standard)	Reference Standards PKA Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium (Standard) is the analytical standard of Bucladesine sodiumn (HY-B0764). This product is intended for research and analytical applications. Bucladesine is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-P3770

Phosphate acceptor peptide	PKC	Others
Phosphate acceptor peptide is a substrate for cAMP-dependent protein kinase (PKA). phosphate acceptor peptide is also a weak PKC inhibitor .

HY-P3929A

PKI (14-24)amide TFA 1 Publications Verification	PKA	Cancer
PKI (14-24)amide TFA is a potent *PKA* inhibitor. PKI (14-24)amide strongly inhibited cyclic AMP-dependent protein kinase activity in the cell homogenate .

HY-P2624

st-Ht31	PAK	Metabolic Disease
st-Ht31 is a membrane-permeable peptide inhibitor of protein kinase A (PKA) anchoring. st-Ht31 induces robust cholesterol/phospholipid efflux. st-Ht31 completely reverses foam cell formation and restores the metabolic health of macrophage .

HY-10230S

Midostaurin-d5 PKC412-d₅; CGP 41251-d₅	Isotope-Labeled Compounds PKC Syk Akt PKA c-Kit	Cancer
Midostaurin-d₅ (PKC412-d₅) is a deuterium labeled Midostaurin. Midostaurin is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC₅₀s ranging from 22-500 nM .

HY-P3930

PKI (5-24),amide IP20-amide	PKA	Neurological Disease
PKI (5-24),amide (IP20-amide) is a 20-residue peptide that corresponds to the active portion of the heat-stable inhibitor protein of cAMP-dependent protein kinase. PKI (5-24),amide is a potent *cAMP-dependent protein* kinase (PKA)** (PKA) inhibitor with a K_i of 2.3 nM .

HY-12880

HA-100 dihydrochloride	Myosin PKA PKC ROCK	Cancer
HA-100 dihydrochloride is a potent **protein kinase inhibitor, with IC₅₀*s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein* kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and *MLC-kinase, respectively. HA-100 dihydrochloride also used as a ROCK* inhibitor .

HY-W288951

FMP-API-1	PKA	Metabolic Disease
FMP-API-1 is an A-kinase anchoring protein (AKAP)-PKA interaction inhibitor. FMP-API-1 binds to the allosteric site of PKA R subunits and increases the activity of PKA and AQP2 in PKA-knockout cell lines of renal cortical collecting ducts (mpkCCD cells). FMP-API-1 has the potential for the study of nephrogenic diabetes insipidus (NDI) .

HY-P10319

RI-STAD-2	PKA	Cardiovascular Disease Cancer
RI-STAD-2 is a high-affinity interfering peptide that regulates the subunit RI of protein kinase A (PKA). RI-STAD-2 interferes with the binding of AKAPs and PKA-RI by simulating the interaction between AKAPs' α-helix domain and PKA-RI's dimerization/anchoration (D/D) domain, thereby affecting *PKA* activity and intracellular localization. RI-STAD-2 can be used to study the role of AKAPs interaction with PKA-RI in pathological processes such as cardiovascular disease and cancer .

HY-134263

8-Br-cAMP-AM	PKA Ras	Cardiovascular Disease
8-Br-cAMP-AM is a cyclic adenosine monophosphate (cAMP) analog that activates two major signal transduction pathways in the heart by mimicking the effects of cAMP: protein kinase A (PKA) and guanosine nucleotide exchange factor (Epac), which is directly activated by cAMP. 8-Br-cAMP-AM can be used to study cardiac ischemia and reperfusion injury .

HY-112348

HA-1004 hydrochloride	Cyclic GMP-AMP Synthase PKA ERK Calcium Channel	Cardiovascular Disease Metabolic Disease
HA-1004 hydrochloride is a selective inhibitor of PKA, which can inhibit lipolysis and induce vascular relaxation. HA-1004 hydrochloride is also a dual inhibitor of cyclic GMP-dependent protein kinase and cyclic AMP-dependent protein (Cyclic GMP-AMP Synthase), and is involved in smooth muscle, second messenger, cyclic AMP and cyclic GMP regulation mechanisms. HA-1004 hydrochloride an antagonist for calcium, that can be used as a vasodilator to inhibit the contraction of rabbit aortic strips, or to antagonize ERK and tyrosine hydroxylase (TH) phosphorylation in morphine abstinence rat models .

Cat. No.	Product Name

HY-L164

Serine/Threonine Kinase Inhibitor Library

2,162 compounds

Protein serine/threonine kinases (PSKs) are protein kinases that use ATP as a high-energy donor molecule to transfer phosphate groups to serine/threonine residues of target protein. As an important signal transduction regulator, serine/threonine kinases can affect the function of target proteins by disrupting enzyme activity or binding of target proteins to other proteins. Serine/threonine kinases are involved in the regulation of immune response, cell proliferation, differentiation, apoptosis and other physiological processes. Serine/threonine kinase inhibitors are an important class of compounds that have been widely studied in cancer, chronic inflammation, autoimmune diseases, aging and other diseases.

MCE designs a unique collection of 2,162 serine/threonine kinase inhibitors, mainly targeting the receptor PKA, Akt, PKC, MAPK/ERK, etc, which is an effective tool for development and research of anti-cancer, anti-chronic inflammatory diseases, anti-autoimmune diseases and anti-aging compounds.

HY-L165

Dopamine Receptor Compound Library

267 compounds

Dopamine receptor (DAR), widely distributed in the brain, plays a key role in regulating motor function, motivation, driving force and cognition. The role of DA is mediated by D1-type (D1, D5) and D2-type receptors (D2S, D2L, D3, D4), which are distributed in presynaptic, postsynaptic and extrasynaptic, projection neurons and interneurons. Each receptor has a different function. D1 and D5 receptors couple with G stimulation sites and activate Adenylyl cyclase. The activation of Adenylyl cyclase leads to the production of the second messenger cAMP, which leads to the production of protein kinase A (PKA), which leads to further transcription in the nucleus. D2 to D4 receptors are coupled to G inhibitory sites to inhibit adenylyl cyclase and activate potassium Ion channel. These receptors utilize phosphorylation cascades or direct membrane interactions to affect the functions of voltage-gated and neurotransmitter-gated channels, cytoplasmic enzymes, and transcription factors. Dopamine receptor plays an important role in daily life.

MCE designs a unique collection of 267 small molecules related to dopamine receptor. It is a good tool for screening drugs from nervous system disease.

Cat. No.	Product Name	Target	Research Area

HY-P0248

Kemptide 1 Publications Verification	PKA	Metabolic Disease
Kemptide is a synthetic heptapeptide that acts as a specific substrate for cAMP-dependent protein kinase (PKA).

HY-P0222

PKI(5-24) 3 Publications Verification	PKA	Others
PKI(5-24) is a potent, competitive, and synthetic peptide inhibitor of *PKA* (cAMP-dependent protein kinase), with a K_i of 2.3 nM. PKI(5-24) corresponds to residues 5-24 in the naturally occurring heat-stable protein kinase inhibitor .

HY-P1290

PKA Inhibitor Fragment (6-22) amide 5 Publications Verification PKI-(6-22)-amide	PKA	Neurological Disease
PKA Inhibitor Fragment (6-22) amide is a highly potent and specific competitive inhibitor of *PKA, with K_i* values of 1.7 nM and 1.6 nM against human and bovine *PKA* catalytic subunits, respectively. The IC₅₀ of PKA Inhibitor Fragment (6-22) amide targeting bovine PKA is 8.6 nM. PKA Inhibitor Fragment (6-22) amide effectively abolishes PKA activity in mouse brain and spinal cord, and exerts in vivo efficacy via intracerebroventricular administration. PKA Inhibitor Fragment (6-22) amide significantly reverses low-dose morphine analgesic tolerance in mice and blocks photoaffinity labeling of cAMP-dependent protein kinase. PKA Inhibitor Fragment (6-22) amide can be applied to research in fields related to the mechanism of morphine analgesic tolerance and skin wound healing .

HY-P1290A

PKA Inhibitor Fragment (6-22) amide TFA 5 Publications Verification PKI-(6-22)-amide TFA	PKA	Neurological Disease
PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependent **protein kinase A (PKA), with a K_i** of 2.8 nM. PKA Inhibitor Fragment (6-22) amide TFA can significantly reverse antinociceptive tolerance in mice .

HY-P10602

PKA Regulatory Subunit II Substrate RII phosphopeptide	PKA	Others
PKA Regulatory Subunit II Substrate (RII phosphopeptide) is a tool peptide derived from the regulatory subunit Type II (RII) of cyclic AMP-dependent protein kinase (PKA). PKA Regulatory Subunit II Substrate is commonly used to mimic the phosphorylation of protein kinases and as a specific substrate for protein phosphatases to assess the activities of these enzymes .

HY-P1597

Malantide 1 Publications Verification	PKA PKC	Cancer
Malantide is a synthetic dodecapeptide derived from the site phosphorylated by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide is a highly specific substrate for *PKA* with a K_m of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts . Malantide is also an efficient substrate for PKC with a K_m of 16 μM .

HY-P2624A

st-Ht31 ammonium	PAK	Metabolic Disease
st-Ht31 ammonium is a membrane-permeable peptide inhibitor of?protein kinase A (PKA) anchoring. st-Ht31 ammonium induces robust cholesterol/phospholipid efflux. st-Ht31 ammonium completely reverses foam cell formation and restores the metabolic health of macrophage .

HY-P3770

Phosphate acceptor peptide	PKC	Others
Phosphate acceptor peptide is a substrate for cAMP-dependent protein kinase (PKA). phosphate acceptor peptide is also a weak PKC inhibitor .

HY-P3929A

PKI (14-24)amide TFA 1 Publications Verification	PKA	Cancer
PKI (14-24)amide TFA is a potent *PKA* inhibitor. PKI (14-24)amide strongly inhibited cyclic AMP-dependent protein kinase activity in the cell homogenate .

HY-P2624

st-Ht31	PAK	Metabolic Disease
st-Ht31 is a membrane-permeable peptide inhibitor of protein kinase A (PKA) anchoring. st-Ht31 induces robust cholesterol/phospholipid efflux. st-Ht31 completely reverses foam cell formation and restores the metabolic health of macrophage .

HY-P3930

PKI (5-24),amide IP20-amide	PKA	Neurological Disease
PKI (5-24),amide (IP20-amide) is a 20-residue peptide that corresponds to the active portion of the heat-stable inhibitor protein of cAMP-dependent protein kinase. PKI (5-24),amide is a potent *cAMP-dependent protein* kinase (PKA)** (PKA) inhibitor with a K_i of 2.3 nM .

HY-P10319

RI-STAD-2	PKA	Cardiovascular Disease Cancer
RI-STAD-2 is a high-affinity interfering peptide that regulates the subunit RI of protein kinase A (PKA). RI-STAD-2 interferes with the binding of AKAPs and PKA-RI by simulating the interaction between AKAPs' α-helix domain and PKA-RI's dimerization/anchoration (D/D) domain, thereby affecting *PKA* activity and intracellular localization. RI-STAD-2 can be used to study the role of AKAPs interaction with PKA-RI in pathological processes such as cardiovascular disease and cancer .

HY-P3920

Cys-Kemptide	PKA	Cancer
Cys-Kemptide is a cysteine-terminated substrate peptide that can used to measure protein kinase A (PKA) activity .

HY-P1597A

Malantide TFA	PKA PKC	Cancer
Malantide TFA is a synthetic dodecapeptide derived from the site phosphorylated by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide TFA is a highly specific substrate for *PKA* with a K_m of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts . Malantide TFA is also an efficient substrate for PKC with a K_m of 16 μM .

HY-P3785

PKI(5-22)amide	PKA	Neurological Disease
PKI(5-22)amide is the active inhibitory fragment of the inhibitor of the cyclic AMP-dependent protein kinase (PKA). PKI(5-22)amide inhibits *PKA* activation, but fails to attenuate homologous desensitization of CRF1 receptors .

HY-P0222A

PKI(5-24) TFA	PKA	Others
PKI(5-24) TFA is a potent, competitive, and synthetic peptide inhibitor of *PKA* (cAMP-dependent protein kinase), with a K_i of 2.3 nM. PKI(5-24) TFA corresponds to residues 5-24 in the naturally occurring heat-stable protein kinase inhibitor .

HY-P3929

PKI (14-24)amide	PKA	Cancer
PKI (14-24)amide is a potent *PKA* inhibitor. PKI (14-24)amide strongly inhibited cyclic AMP-dependent protein kinase activity in the cell homogenate .

HY-P10464

Tat-AKAP79 (326-336)	TRP Channel	Neurological Disease Inflammation/Immunology
TAT-AKAP79 326-336 is a cytoosmotic peptide. TAT-AKAP79 326-336 mimics a specific region on the AKAP79 protein that binds to TRPV1 ion channels (amino acid sequence 326-336). TAT-AKAP79 326-336 inhibits the sensitization of TRPV1 and reduce the overresponse of TRPV1 channels to stimuli caused by the activation of cellular kinases such as protein kinase A (PKA) and protein kinase C (PKC) by inflammatory mediators. TAT-AKAP79 326-336 can be used to study the mechanism of pain transduction and inflammatory hyperalgesia .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-15141

Staurosporine Maximum Cited Publications 207 Publications Verification Antibiotic AM-2282; STS; AM-2282	Infection Structural Classification Alkaloids Microorganisms Classification of Application Fields Marine natural products Marine microorganism Disease Research Fields Indole Alkaloids Source Classification	PKC PKA Apoptosis Bacterial Fungal Antibiotic
Staurosporine is a potent, ATP-competitive and non-selective inhibitor of protein kinases with IC₅₀s of 6 nM, 15 nM, 2 nM, and 3 nM for PKC, *PKA, c-Fgr, and Phosphorylase kinase* respectively. Staurosporine also inhibits TAOK2 with an IC₅₀ of 3 μM. Staurosporine is an apoptosis inducer .

HY-N6732

K-252a 25+ Cited Publications SF2370; Antibiotic K 252a; Antibiotic SF 2370	Alkaloids Structural Classification Microorganisms Classification of Application Fields Inflammation/Immunology Disease Research Fields Indole Alkaloids Source Classification	Autophagy PKA PKC Trk Receptor CaMK
K-252a, a staurosporine analog, inhibits **protein kinase, with IC₅₀** values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca ²⁺/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively . K-252a is a potent inhibitor (IC₅₀ of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene .

HY-N0281

Daphnetin 5+ Cited Publications 7,8-Dihydroxycoumarin	Daphne Classification of Application Fields Thymelaeaceae Coumarins Phenols Polyphenols Phenylpropanoids Plants Disease Research Fields Source Classification Cancer	EGFR PKA PKC Autophagy Apoptosis AMPK Akt mTOR Reactive Oxygen Species (ROS) Caspase Bcl-2 Family PARP Parasite
Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative can be found in plants of the Genus Daphne, is a potent, oral active **protein kinase inhibitor, with IC₅₀s** of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively. Daphnetin triggers ROS-induced cell apoptosis and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway. Daphnetin has anti-inflammation activitity and inhibits TNF-α, IL-1β, ROS, and MDA production. Daphnetin has schizontocidal activity against malaria parasites. Daphnetin can be used for rheumatoid arthritis , cancer and anti-malarian research .

HY-108262

UCN-02 7-epi-Hydroxystaurosporine	Structural Classification Microorganisms Classification of Application Fields Antibiotics Antibacterial Disease Research Disease Research Fields Other Antibiotics Source Classification Cancer	PKC PKA
UCN-02 (7-epi-Hydroxystaurosporine) is a selective protein kinase C (PKC) inhibitor with a PKC IC₅₀ value of 62 nM and a *PKA* IC₅₀ value of 0.25 μM. UCN-02 can be produced by Streptomyces strain N-126. UCN-02 can be used for the research of breast carcinoma .

HY-15141R

Staurosporine (Standard) Antibiotic AM-2282 (Standard); STS (Standard); AM-2282 (Standard)	Alkaloids Structural Classification Microorganisms Marine natural products Marine microorganism Indole Alkaloids Source Classification	Reference Standards PKC PKA Apoptosis Bacterial Fungal Antibiotic
Staurosporine (Standard) is the analytical standard of Staurosporine. This product is intended for research and analytical applications. Staurosporine is a potent, ATP-competitive and non-selective inhibitor of protein kinases with IC50s of 6 nM, 15 nM, 2 nM, and 3 nM for PKC, PKA, c-Fgr, and Phosphorylase kinase respectively. Staurosporine also inhibits TAOK2 with an IC50 of 3 μM. Staurosporine is an apoptosis inducer[1][2][3][4][5].

HY-N0521R

(-)-Gallocatechin (Standard)	Structural Classification Flavonoids Flavanols Phenols Polyphenols Camellia sinensis (L.) O. Ktze. Plants Source Classification Theaceae	Reference Standards Reactive Oxygen Species (ROS)
(-)-Gallocatechin (Standard) is the analytical standard of (-)-Gallocatechin. This product is intended for research and analytical applications. (-)-Gallocatechin, an epimer of (-)-Epigallocatechin (EGC), is contained in various tea products. (-)-Gallocatechin has antioxidant activities. (-)-Gallocatechin is the main active component in green tea extract (HTP-GTE) responsible for its effect of improving age-related cognitive impairments involving protein kinase A (PKA) pathway .

HY-121197

Balanol Ophiocordin; Azepinostatin	Structural Classification Natural Products Microorganisms Source Classification	MARCKS PKA PKC
Balanol (Ophiocordin; Azepinostatin) is a potent and ATP competitive *PKC/PKA* inhibitor against human PKC isozymes α, β-I, β-II, γ, δ, ε, η (IC₅₀s=4-9 nM) and ζ (IC₅₀=150 nM). Balanol also blocks the phosphorylation of *cyclic AMP response element-binding protein* (CREB) and myristoylated alanine-rich C kinase substrate (MARCKS)*. Balanol can be isolated from the fungus Verticillium balanoides* .

HY-N0281R

Daphnetin (Standard) 7,8-Dihydroxycoumarin (Standard)	Structural Classification Daphne Thymelaeaceae Coumarins Phenols Polyphenols Phenylpropanoids Plants Source Classification	Reference Standards EGFR PKA PKC Autophagy Apoptosis AMPK Akt mTOR Reactive Oxygen Species (ROS) Caspase Bcl-2 Family PARP Parasite
Daphnetin (Standard) is the analytical standard of Daphnetin. This product is intended for research and analytical applications. Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative can be found in plants of the Genus Daphne, is a potent, oral active protein kinase inhibitor, with IC₅₀s of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively. Daphnetin triggers ROS-induced cell apoptosis and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway. Daphnetin has anti-inflammation activitity and inhibits TNF-α, IL-1 , ROS, and MDA production. Daphnetin has schizontocidal activity against malaria parasites. Daphnetin can be used for rheumatoid arthritis , cancer and anti-malarian research .

Species:	Human (2)
Tag:	Tag Free (2)
Source:	Sf9 insect cells (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P705862

	PKA/PRKACA Protein, Human (K48R, L96Q, M121L, V124A, Q182K, T184A) PRKACA; cAMP-dependent protein kinase catalytic subunit alpha; PKA C-alpha	Human	E. coli

HY-P702637

	PRKACB Protein, Human (Active, sf9) PRKACB; protein kinase, cAMP-dependent, catalytic, beta; cAMP-dependent protein kinase catalytic subunit beta; PKACb; PKA C-beta; protein kinase A catalytic subunit beta; cAMP-dependent protein kinase catalytic beta subunit isoform 4ab; PKACB; MGC9320; MGC41879; DKFZp781I2452	Human	Sf9 insect cells
	PRKACB Protein, Human (sf9) is the recombinant human-derived PRKACB, expressed by Sf9 insect cells , with tag Free labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-10230S

Midostaurin-d5
Midostaurin-d₅ (PKC412-d₅) is a deuterium labeled Midostaurin. Midostaurin is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC₅₀s ranging from 22-500 nM .

HY-W751179

Midostaurin-13C6

Midostaurin- ¹³C₆ (PKC412- ¹³C₆) is the ¹³C-labeled Midostaurin (HY-10230). Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC₅₀s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .

Host:	Rabbit (5)
Reactivity:	Human (5) Rat (5) Mouse (3) Pig (1)
Application:	IHC-P (1) ICC/IF (2) IP (1) WB (5)
Isotype:	IgG (5)
Conjugation:	Non-conjugated (5)
Clonality:	Polyclonal (2) Monoclonal (1) Recombinant (1)
Modification:	Phosphorylated (2) Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P81127

	PKA alpha+beta Antibody PRKACA/PRKACB; PRKACA + PRKACB; PKA alpha + beta; PKA alpha; PKA beta; cAMP dependent protein kinase alpha catalytic subunit; cAMP dependent protein kinase beta catalytic subunit; cAMP dependent protein kinase catalytic subunit alpha; cAMP dependent protein kinase catalytic subunit beta; DKFZp781I2452; MGC102831; MGC41879; MGC48865; MGC9320; PKA C alpha; PKA C beta; PKACA; PKACB; PRKACA; PRKACB; protein kinase A catalytic subunit alpha; protein kinase A catalytic subunit; protein kinase A catalytic subunit beta; protein kinase cAMP dependent catalytic alpha; protein kinase cAMP dependent catalytic beta; cAMP dependent protein kinase catalytic subunit alpha isoform 1; cAMP-dependent protein kinase catalytic subunit alpha; KAPCA_HUMAN; KAPCB_HUMAN; PKA C alpha; PKA C-alpha; PKACA; PRKACA; protein kinase A catalytic subunit; protein kinase cAMP dependent catalytic alpha.	WB, ICC/IF	Human, Mouse, Rat
	PKA alpha+beta Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to PKA alpha+beta.

HY-P810621

	Phospho-PKA alpha/beta/gamma (catalytic subunit) (Thr197) Antibody (YA9883) PRKACA/PRKACB; PRKACA + PRKACB; PKA alpha + beta; PKA alpha; PKA beta; cAMP dependent protein kinase alpha catalytic subunit; cAMP dependent protein kinase beta catalytic subunit; cAMP dependent protein kinase catalytic subunit alpha; cAMP dependent protein kinase catalytic subunit beta; DKFZp781I2452; MGC102831; MGC41879; MGC48865; MGC9320; PKA C alpha; PKA C beta; PKACA; PKACB; PRKACA; PRKACB; protein kinase A catalytic subunit alpha; protein kinase A catalytic subunit; protein kinase A catalytic subunit beta; protein kinase cAMP dependent catalytic alpha; protein kinase cAMP dependent catalytic beta; cAMP dependent protein kinase catalytic subunit alpha isoform 1; cAMP-dependent protein kinase catalytic subunit alpha; KAPCA_HUMAN; KAPCB_HUMAN; PKA C alpha; PKA C-alpha; PKACA; PRKACA; protein kinase A catalytic subunit; protein kinase cAMP dependent catalytic alpha.	WB	Human, Mouse, Rat
	Phospho-PKA alpha/beta/gamma (catalytic subunit) (Thr197) Antibody (YA9883) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-PKA alpha/beta/gamma (catalytic subunit) (Thr197).

HY-P80847

	Phospho-PKA R2/PKR2 (Ser99) Antibody 2 Publications Verification PRKAR2A; PKR2; PRKAR2; cAMP-dependent protein kinase type II-alpha regulatory subunit	WB, IHC-P, ICC/IF, IP	Human, Mouse, Rat, Pig
	Phospho-PKA R2/PKR2 (Ser99) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-PKA R2/PKR2 (Ser99).

HY-P82006

	PKA RI alpha Antibody (YA1751) PRKAR1A; PKR1; PRKAR1; TSE1; cAMP-dependent protein kinase type I-alpha regulatory subunit; Tissue-specific extinguisher 1; TSE1	WB	Human, Rat
	PKA RI alpha Antibody (YA1751) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PKA RI alpha.

HY-P82006A

	PKA RI alpha Antibody (YA1751)(PBS only) PRKAR1A; PKR1; PRKAR1; TSE1; cAMP-dependent protein kinase type I-alpha regulatory subunit; Tissue-specific extinguisher 1; TSE1	WB	Human, Rat
	PKA RI alpha Antibody (YA1751) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PKA RI alpha.